Showing results (411-420 of 546) with videos related to

Sort By:
Pageof 55
Nanoscale|February 27, 2026
Glycosylated carbon nanodots as multivalent blockers of lectin-driven viral entry: structural insights and antiviral performanceGema Nieto-Ortiz, Justo Cabrera-González, Fátima Lasala, et al.
Plos Pathogens|May 20, 2021
DC/L-SIGN recognition of spike glycoprotein promotes SARS-CoV-2 trans-infection and can be inhibited by a glycomimetic antagonistMichel Thépaut, Joanna Luczkowiak, Corinne Vivès, et al.
Medicina|October 29, 2000
[Hantavirus pulmonary syndrome in southern Argentina]M E Lázaro, A J Resa, C M Barclay, et al.
BJA Open|August 17, 2023
Incidence of acute kidney injury after noncardiac surgery in patients receiving intraoperative dexmedetomidine: a retrospective studyManuel A Paredes-Flores, Javier D Lasala, Teresa Moon, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|October 6, 2022
Patient outcomes and adherence to an enhanced recovery pathway for open gynecologic surgery: a 6-year single-center experienceJudy Hayek, Andres Zorrilla-Vaca, Larissa A Meyer, et al.
Cancer Research|April 15, 1990
Basic fibroblast growth factor-like activity and receptors are expressed in a human glioma cell lineR S Morrison, J L Gross, W F Herblin, et al.
Revista Argentina De Microbiologia|June 18, 1998
[Detection of the viral load and its use as a virological marker in the follow-up of HIV-1-positive patients]V L Hodara, A Monticelli, J Benetucci, et al.
European Journal of Clinical Pharmacology|January 20, 2024
The lack of head-to-head randomised trials and the consequences for patients and national health service: The case of non-small cell lung cancerRuggero Lasala, Alessia Romagnoli, Fiorenzo Santoleri, et al.
Journal of Medical Virology|November 1, 2022
Cross neutralization of SARS-CoV-2 omicron subvariants after repeated doses of COVID-19 mRNA vaccinesJoanna Luczkowiak, Gonzalo Rivas, Nuria Labiod, et al.
The Journal of Infectious Diseases|December 28, 2021
Neutralizing Response Against SARS-CoV-2 Variants 8 Months After BNT162b2 Vaccination in Naive and COVID-19-Convalescent IndividualsJoanna Luczkowiak, Nuria Labiod, Gonzalo Rivas, et al.
Pageof 55